



The Science to See™

Neuro Kinetics, Inc. and Walter Reed National Military Medical Center sign a Cooperative Research And Development Agreement to Study Traumatic Brain Injury

PITTSBURGH, PA (July 20, 2017) — Neuro Kinetics, Inc. (NKI), announced today that it is one of only a few vendors chosen to sign a Cooperative Research and Development Agreement (CRADA) with the Department of Defense's (DoD) Walter Reed National Military Medical Center (WRNMMC). The study will evaluate the sensitivity and specificity of oculomotor, vestibular and reaction time for subjects with a history of Traumatic Brain Injury (TBI). Oculomotor assessment is the only non-invasive neuro-assessment method that meets the criteria established by the DoD's NonInvasive Neurological Assessment Devices Integrated Product Team, a part of the US Army Medical Material Development Activity (USAMMDA).

Collaborating under this CRADA are Alex Kiderman, Ph.D., Chief Technology Officer of NKI, and John King, Ph.D., WRNMMC and others. Dr. Kiderman notes, "Clinicians and researchers at WRNMMC are investigating solutions aimed at the diagnosis and monitoring of concussions. We are pleased to collaborate on this research effort, which should contribute to elevating the standard of evaluating patients with mTBI."

The study is designed as a prospective, non-randomized trial comparing a group of normal controls without a history of TBI to another group of participants who have a confirmed history of TBI. Subjects are to be tested using three devices including NKI's I-PAS™ (I-Portal® Portable Assessment System).

I-PAS is an easy-to-use, portable head-mounted system that leverages the company's commercial I-Portal testing technology running an integrated, multi-modal battery of OVRT (oculomotor, vestibular, and reaction time) tests. Recent studies have shown success with NKI's I-Portal systems when measuring mild traumatic brain injury (mTBI) symptoms. High sensitivities and or specificities are reported acute for mTBI's and during recovery. Prior studies assessing I-Portal's potential for concussion assessment reported sensitivities of 97% with specificities of 89%. Those promising results can be found in publications online at <http://tinyurl.com/y845ulrw> and <http://tinyurl.com/y7ava7ka>.

Concussions – mild TBI's or mTBI—remain a growing public health concern, particularly in the absence of objective diagnostic devices. Physicians are eager for devices that provide objective measures of concussion symptoms.

To learn more about NKI, please visit www.neuro-kinetics.com.



The Science to See™

MEDIA CONTACTS:

Susan Zelicoff

VP Marketing and Sales Neuro Kinetics, Inc.

Office: 412-963-6649

susan@neuro-kinetics.com

ABOUT NKI The Science to See™

Neuro Kinetics, Inc. (NKI) is the leader in clinical eye-tracking and non-invasive neuro-otologic diagnostic testing. The eye is the portal to the brain and research has shown the detection of abnormal eye responses are used to diagnose more than 200 diseases and medical conditions.

With over 140 I-Portal installations, NKI's FDA cleared I-Portal® devices are sold to audiologists, ENT's, neurotologists, neuro-ophthalmologists and neurologists around the globe. The company's cleared patented diagnostic platforms include the I-Portal® NOTC (Neuro-Otologic Test Center), I-Portal® VNG (Video Nystagmography) and I-Portal® VOG (Video Oculography), along with related accessories, software, training and support services.